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Purpose. Anti-cancer dendritic cell (DC) vaccines require the DC to relocate to 
lymph nodes (LN) to trigger immune responses. However, these migration rates are 
typically very poor. Improving the targeting of ex vivo generated DC to LN might 
increase vaccine efficacy and reduce costs. We investigated DC migration in vivo in 
humans in different conditions.  
Experimental design. HLA-A*02:01 melanoma patients were vaccinated with 
mature DC loaded with tyrosinase and gp100 peptides together with keyhole limpet 
hemocyanin (KLH) (NCT00243594). For this study, patients received an additional 
intradermal (i.d.) vaccination with 111In-labeled mature DC. The injection site was 
pretreated with nonloaded, activated DC, TNFα or Imiquimod; GM-CSF was co-
injected or smaller numbers of DC were injected. Migration was measured by 
scintigraphy and compared to an intra-patient control vaccination. In an ex vivo 
tissue model, we measured CCL21-directed migration of 19F-labeled DC over a 
period of up to 12 hours using 19F MRI to supplement our patient data. 
Results. Pretreatment of the injection site induced local inflammatory reactions but 
did not improve migration rates. Both in vitro and in vivo, reduction of cell numbers to 
5×106 or less cells per injection improved migration. Furthermore, scintigraphy is 
insufficient to study migration of such small numbers of 111In-labeled DC in vivo. 
Conclusion. Reduction of cell density, not pretreatment of the injection site, is 
crucial for improved migration of DC to LNs in vivo. 
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Statement of translational relevance  
 
To trigger an effective immune response, ex vivo generated tumor antigen-loaded 
DC need to relocate to LN. Intradermal (i.d.) delivery is commonly used, due to its 
feasibility; however, migration rates never exceeded 4%. Increasing the numbers of 
ex vivo generated DC reaching  LN might therefore increase the vaccine-specific 
response and reduce costs. 
We investigated 111In-labeled DC migration in vivo in humans after pretreatment of 
the injection site, using unloaded but activated DC, TNFα or a synthetic TLR7/8 
ligand; or co-injection with GM-CSF. Furthermore, we developed an in vitro assay to 
measure human DC migration in a sensitive and standardized manner.  
We show that reduction of cell density, not pretreatment of the injection site, is 
crucial for improved migration of DC to LN in vivo. However, current imaging 
modalities for in vivo tracking of DC are insufficient to study migration of small 
numbers of 111In-labeled DC in the clinic. 
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Introduction  
Cellular therapy in cancer patients aims to activate the immune system in a highly 
specific response against the tumor. In most studies, autologous antigen-presenting 
cells, principally dendritic cells (DC), are activated and loaded with tumor antigen ex 
vivo (1). To trigger an effective immune response, the DC need to relocate to 
immune reactive sites, such as lymph nodes (LN) upon injection back into the 
patient. Different routes are used to administer the DC to the patients, of which 
intradermal (i.d.) injection is the most frequently used (2). The biodistribution of DC 
after vaccination has been studied in humans, primarily using 111In or 99mTc-labeled 
DC and scintigraphy (2). However, even though about 20 clinical trials have been 
carried out with DC delivered intradermally, the number of cells that reach a LN has 
never reproducibly exceeded 4% of the total cells injected (2). Why migration of 
mature DC from the vaccination site is so poor is still unknown. Several reasons 
have been suggested, for example the lack of an inflammatory microenvironment 
which would promote emigration of immune cells to afferent lymphatic vessels. In a 
mouse model, the migration of bone marrow derived DC into the draining LN could 
be dramatically increased by pretreating the injection site (3, 4). The skin was 
injected with either an extra dose of DC, pro-inflammatory cytokines (TNFα or IL-1α) 
or Toll-like receptor ligands before injection of the vaccine-DC. This pretreatment of 
the skin resulted in a five to ten-fold increase in the number of DC in the draining LN 
that correlated with a similar increase in T cell activation. Other parameters of DC 
delivery might also contribute to more efficient emigration of DC from the skin to the 
draining LN, e.g. the frequency of delivery, the infrastructure in terms of vascular and 
lymphatic networks at site of transplant and the local availability of oxygen and 
nutrients (5-7).Thus conditioning the injection site, and perhaps indirectly the 
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draining LN, may stimulate the emigration of DC from the skin and directly improve 
the clinical efficacy of DC-based therapy. Given this multitude of parameters, in vitro 
cell migration assays are warranted, as they allow high-throughput screening of 
influences of single parameters or combinations of parameters. The common in vitro 
cell migration assays that do exist, such as those based on microscopy or plate-
based migration assays, have some major drawbacks: these techniques typically 
only work with small numbers of cells or non-opaque samples and thus do not 
replicate clinical conditions. Furthermore, most techniques assess migration in two-
dimensional setting, whereas in vivo migration requires motility in 3D. Thus, studying 
cell migration in vitro in a sensitive and quantitative manner for clinical application is 
extremely challenging, and not readily feasible with current technology (2). 
In this study, we investigated DC migration in vivo in humans after pretreatment of 
the injection site, using nonloaded but activated DC, TNFα or Imiquimod (a synthetic 
TLR7/8 ligand), to induce a local inflammatory microenvironment; or co-injection with 
GM-CSF to enhance DC survival. We tracked 111In-labeled vaccine-DC over a period 
of 48 hours by planar scintigraphy and compared migration to the LN to a 
standardized control vaccination in the same patient. Furthermore, we modified an in 
vitro assay that closely reflects in vivo vaccination conditions to measure human DC 
migration in a standardized manner in tissue samples (8). By using this model, we 
measured CCL21 directed migration of 19F-labeled vaccine-DC over a period of up to 
12 hours using 19F MRI. We show that reduction of cell density, not pretreatment, at 
the injection site is crucial for improved DC migration in vivo. In particular, we found 
that cell numbers greater than 1 million reduced migration both in vitro and in vivo. 
Furthermore, current clinical imaging modalities for clinical in vivo tracking of DC are 
insufficient to study migration of small numbers of DC in human studies.  
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Materials and Methods 
 
DC vaccination in melanoma patients  
In this study, stage III and IV melanoma patients (according to American Joint 
Committee on Cancer criteria) who were scheduled for regional LN dissection with 
either curative or palliative intention were included. Additional inclusion criteria 
included HLA*A02:01 phenotype, melanoma expressing the melanoma-associated 
antigens gp100 and tyrosinase, and WHO performance status 0 or 1. Patients with 
brain metastases, serious concomitant disease, or a history of a second malignancy 
were excluded (see Supplementary Table 1 for details). The study was approved by 
the Regional Review Board, and written informed consent was obtained from all 
patients. Clinical trial registration number is NCT00243594.  
Patients received a DC vaccine via intradermal or intranodal injection, either with or 
without systemically administered IL-2. Intranodal vaccination was conducted in a 
clinically tumor-free LN under ultrasound guidance. Intradermal vaccination was 
conducted at 5 to 10 cm distal from a (preferably inguinal) clinically tumor-free LN, by 
clinicians with extensive experience with the procedure (W.J. Lesterhuis, E.H.J.G. 
Aarntzen, C.J.A. Punt). Because the first vaccination was administered 1-2 day 
before regional LN dissection, presumably a significant benefit to the patient could 
not be expected. For this reason, the first vaccination always consisted of an 
injection of 111In-labeled, but not peptide-pulsed and not keyhole limpet hemocyanin 
(KLH)-loaded DCs on the side of the LN dissection, and an injection of peptide-
pulsed DCs on the contralateral side. The latter vaccine could be 111In-labeled or not. 
The DC vaccine consisted of autologous mature DCs pulsed with gp100 and 
tyrosinase peptides and KLH. Patients received 1 cycle consisting of 4 DC 
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vaccinations administered at a biweekly interval. IL-2 was administered by 
subcutaneous injections (at 9 MIU) once daily for 1 week starting 3 days after each 
DC vaccination. Twenty-four to 48 hours after the first vaccination, a radical LN 
dissection was conducted. One to 2 weeks after the fourth vaccination, a DTH test 
was conducted (9). All patients who remained free of disease progression after the 
first vaccination cycle were eligible for 2 maintenance cycles, each at 6-month 
intervals and each consisting of 3 biweekly intranodal vaccinations without IL-2. 
Patients were considered evaluable when they had completed the first vaccination 
cycle. Vaccine-specific immune response was the primary endpoint, as reported in 
previous publication (10).  
 
DC preparation and characterization 
KLH-loaded DCs were generated from peripheral blood mononuclear cells (PBMC) 
and matured with autologous monocyte-conditioned medium containing 
prostaglandin E2 (10 mg/mL; Pharmacia & Upjohn) and recombinant TNF-a (10 
ng/mL; provided by Dr. G. Adolf, Bender Wien GmbH), as described (29, 30). This 
procedure gave rise to mature DCs meeting the release criteria (29) and detailed 
vaccine phenotype is reported in previous publication (10). 
 
Peptide pulsing 
DCs were pulsed with the HLA class I gp100-derived peptides gp100:154–162 and 
gp100:280–288 and the tyrosinase-derived peptide tyrosinase: 369–377 (31–33). 
Peptide pulsing was conducted as described (13), and cells were resuspended in 0.1 
mL for injection.  
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111In-labeling and scintigraphy 
For 111In labeling, 111In-oxine (Covidien, Petten, The Netherlands) in 0.1 M Tris-HCl 
(pH 7.0) was added to mature DC for 15 min at room temperature as described 
previously (11). This results in 5 μCi per 15×106 cells. Cells were washed three times 
with PBS. Radiolabeling efficiency was determined by measuring activity in both the 
cell pellet and the washing buffer. 
For this study, patients received an extra injection prior to scheduled RLND as 
mentioned above, or during the course of vaccination with increasing numbers of DC 
resuspended in 100 μl of injection liquid and distributed over one or multiple injection 
sites, as indicated. At 24 hours and 48 hours post-injection, migration of DC was 
imaged by planar scintigraphy (256 × 256 matrix, 174 and 247 keV 111In photopeaks 
with 15% energy window) of the injection depot and corresponding LN basin with a 
gamma camera (Siemens ECAM, Hoffman Estates, Ill) equipped with medium 
energy collimators). Migration was quantified by region of interest (ROI) analysis of 
the individual nodes visualized on the images and expressed as the relative fraction 
of 111In-labeled DC that had migrated from the injection depot to draining LN.  
 
19F-labeling and MR imaging in vitro 
For 19F labeling, the label particles were prepared using perfluoro-[15]-crown-5 ether 
(C10F20O5) (Exfluor Research Corp., Round Rock, TX, USA ) and PLGA (Resomer 
RG 502 H, lactide: glycolide molar ratio 48:52 to 52:48; Boehringer Ingelheim, 
Ingelheim am Rhein, Germany) as described (12). 10 mg per 106 cells of particles 
was added to the DC culture at day 3. Upon harvesting (day 8), cells were washed 
three times in PBS to remove excess particles. 
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For the migration assay, the technique was adapted from (8) to replace the gel 
scaffold with a tissue sample, in this case bovine muscle. DC were injected as a 
bolus in the center of a 2 ml Eppendorf tube filled with a single piece of tissue, 
leaving about 1cm above the tissue as space for medium (see Fig 3a). The region 
below the cells formed the control layer to account for nonspecific cell movement or 
sinking due to gravity, and the region above was the migration region through the 
use of a chemokine gradient consiting of 0.2μg recombinant human CCL21 (R&D 
Systems, Minneapolis, MN, USA). 
1H and 19F images were acquired on a 7T horizontal bore MR-system with a 1H/19F 
volume coil. 1H 2D spin echo images were taken for localization and nine 19F 
chemical shift spectroscopic imaging (CSI) was done every hour for up to 9 hours, to 
measure cell migration. Proton images were acquired with TR/TE=1000/22 ms and 
0.125×0.125×1 mm3 resolution. A 0.94×0.94×10 mm3 matrix size with 
TR/TE=400/2.94ms was used for CSI. The sample was sealed and not moved for 
the duration of the imaging experiment. Temperature was maintained at 37 oC using 
regulated warm air flows. 
 
Histology 
Sections (5 μm) of the resected skin from the injection sites were stained with 
hematoxilin. The staining protocol was done as in (13). Similar sections were cut 
from the tissue used for the ex vivo migration assay. These were stained with 
hematoxilin and an antibody against carbonic anhydrase 9 (CAIX; Novus 
Biologicals)..  
 
Statistical analyses 
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All comparisons were performed using a two-tailed unpaired t-test with the 
intradermal migration after 48 hours without pretreatment as comparator.  
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Results  
 
DC migration to LN is poor after intradermal vaccination 
In current and previous studies (10, 14), migration of DC to skin-draining LN after i.d. 
injection (n=18) was monitored by labeling the DC vaccine with 111In and subsequent 
scintigraphy of injected region (14, 15). Figure 1A shows the percentage of migrating 
DC after i.d. injection of 15×106 DC at 24 or 48 hrs post-injection. The average 
migration achieved was 1.2% after 24 hours and 1.4% after 48 hrs, indicating that 
most of the migration occurred within 24 hrs after injection. Migration rates never 
exceeded 4% of the total cells injected. Figure 1B shows representative scintigraphs, 
with the arrow indicating a pretreated site. 
 
The induction of local inflammation of does not improve DC migration 
Based on data from mice studies (3, 4), we investigated whether pretreatment of the 
injection site to create a local inflammatory microenvironment, optimized DC 
migration. To this end, we pretreated the injection sites with TNFα (n=3), Imiquimod 
(n=4) or unloaded but activated DC 6 hours (n=3) or 24 hours (n=3) prior to 
vaccination (Figures 1A,B). In patients pretreated with TNFα or activated DC, the 
contralateral administration of 15×106 111In-labelled vaccine-DC served as intra-
patient control. Although the migration from the pretreated site was higher than in the 
control site in the majority of those patients, it still did not exceeded 4% and did not 
significantly increase migration compared to unconditioned sites.  
Our previous studies have shown that vaccine-DC rapidly lose viability at the 
injection site after intranodal or intradermal delivery, which might contribute to 
defective migration to LN (15). Addition of GM-CSF as an adjuvant during DC 
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vaccination might increase the survival of DC and thereby increase migration rates. 
Three patients were injected with 15×106 DC in normal saline containing 14×104 IU 
GM-SCF. Although the percentage of migrating cells after 48hours was higher than 
average in 2 of 3 patients, migration was still within the established range. Of note, 
the induration at the site of injection was markedly larger than after injection of DC 
alone, suggesting random migration into surrounding dermis. 
Lastly, we pretreated the injection site of 4 patients by Imiquimod application every 
12 hours for 2 days prior to vaccination. Again, no significant changes in migration 
rates were documented. Overall, the effects of pretreatment were limited and did not 
significantly improve subsequent migration of vaccine-DC to the draining LN.   
 
Local cell density is limiting factor 
We performed histological analysis of the pretreatment injection sites 48 hours post-
injection in order to validate our imaging findings. Injection of DC consistently 
induced local inflammation, demonstrated by infiltrates of leukocytes around vessels 
in the dermis, mainly neutrophils and eosinophils. The number of lymphocytes in the 
dermis increased, compared to normal skin. Pretreatment of the injection site with 
either TNFα (Figure 2A,B) or unloaded DC (Figure 2C); or co-injection with GM-CSF 
(Figure 2D) induced some inflammation, as evidenced by the infiltration of 
leukocytes. However, this did not affect DC emigration.  
Histology showed that macrophages had infiltrated the dermis and subcutis around 
the injection site. In areas with SPIO+ cells were enlarged and exhibited pale pink 
nuclei, typical for necrotic cells. Thus, the histological evidence shows that DC die at 
the site of injection and invariably induce an inflammatory response consisting of 
macrophages and neutrophils. As no apparent differences were noted after different 
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pretreatment regimens, together with the notion that dying vaccine-DC were found at 
higher rates with larger numbers of injected cells; these data suggests that it must be 
the local cell density itself that hampers efficient emigration of the injection site.  
 
An in vitro assay to study migration of small numbers of DC  
To test this hypothesis, we adapted a novel assay we developed to mimic clinical 
vaccine conditions and which allows reliable quantification of reduced numbers of 
cells (8). The assay was modified to use a tissue sample instead of a gel scaffold, as 
done previously. DCs were cultured as used in patient vaccinations, with the addition 
of a labeling step for 19F detection. This labeling has previously been shown to have 
no effect on the DCs, including their migration (8), (Figure 3A). The grid overlay 
shows the voxels used in the 19F CSI scans. Imaging was carried out at hourly 
intervals without moving the sample, and the temperature was regulated. A control 
area under the cell injection was used to measure passive cell movement due to 
gravity. CCL21 was used to create a chemokine gradient for active CCR7-mediated 
migration. The percentage of total cells that migrated was calculated to represent the 
migratory cells. Figure 3B shows representative cell numbers at 1, 5 and 9 hours 
after injection of 5 x 106 DCs. The migratory and control regions are highlighted. 
 
Reducing the cell density improves migration rates 
The following figure (Figure 4A) shows the migration over time for 5×106 DCs, for the 
migratory region (red) and the control region under the cell layer (blue). These data 
show that clear migration which is absent in the control region. The overall numbers 
of cells that migrated were 3×104 and 4.5×105 with 5×105 and 5×106 cells, 
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respectively, demonstrating the sensitivity of this assay. Figure 4B summarizes the 
results of three individual experiments with varying cell numbers in the gel scaffold. 
The data indicate that indeed increasing cell number suppresses migration. Thus, 
the percent of migratory cells is nearly 3% with 0.5 x106 and 0% with 15 x106 DC. 
Finally, histological analyses on the tissue samples, taken over and around the 
injection site, were analysed (Figure 4C). Extensive hypoxia was observed at the 
injection site (CAIX stain (brown); top panel). Furthermore, at the lower cells 
numbers, we observed trains of migratory cells (lower panels). These trains appear 
to be migrating along the muscle tissue, and were completely absent with samples 
with 15 and 10 x 106 million DCs. 
 
Planar scintigraphy not sufficient for imaging of low numbers of injected cells 
in vivo 
Finally, we compared the migration data obtained in vitro using our 19F MRI assay 
with the clinical data obtained using scintigraphy on 111In-labeled DCs (Fig. 5a). Due 
to the difficulties of testing different conditions in patients, our clinical data only 
reflects migration with 105 and 106cells per injection. Five injections of 1×106 or 5 
injections of 1×105 cells were injected intradermally, at different sites 1 centimeter 
apart. The average percentage of migratory cells was significantly increased to 
5×106 cells compared to 1 injection with 15×106 cells; 1.9% (p<0.05), but not with 
5×105 cells; 0.5% (not significant) respectively. Thus, lowering the number of cells to 
106 cells per injection improved migration by about 1.5-fold, in terms of percentage, 
relative to a single bolus injection of 15×106 DC. So, trend in percentage of migratory 
cells is comparable with our in vitro data for 5 and 10×106 cells, respectively. The 
percentage of migratory DC in patients would be expected to be highest with 0.5×106 
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cells, as predicted by the in vitro results. However, this apparent discordance is due 
to the sensitivity limits of scintigraphy (16), where the smaller numbers of migratory 
cells were probably simply not detected due to sensitivity issues.
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Discussion 
The interest in cellular therapy is increasing at fast pace, in particular research 
towards harnessing immune cells for anti-cancer therapy, which has been revived by 
recent key developments (17, 18). Owing to their unique immune stimulating 
properties, DCs have been the “hot” target for anti-cancer immunotherapy in the past 
decades. Endowed with knowledge of the crucial steps which underlie successful 
induction of tumor specific immune responses, various vaccination parameters have 
been optimized in previous studies (19). At this point, the paradigm shifts from small 
proof-of-principle studies to large randomized controlled trials. Accordingly, attention 
should be paid to the feasibility of cellular therapy at large scale. Intradermal 
injection of DC for immunotherapy is generally the easiest approach and therefore 
preferred in most clinical trials involving DC-based therapy (2). Unfortunately only 
limited numbers of DC will reach the draining LN. Improving the efficiency of DC 
migration might therefore increase the immunological response (20) and reduce 
costs while potentially improving patient response. In mice, immune responses were 
dose dependent (3, 21) and could be increased by conditioning of the injection site. 
We show here that migration rates of human monocyte-derived DC after intradermal 
injection in melanoma patients could not be increased by pretreatment to induce a 
pro-inflammatory microenvironment at the injection site. Instead, by using a novel 
model, we demonstrate in vitro and in vivo that a reduction of cell numbers at the 
injection site is key to improved migration.  
A number of factors might explain the discrepancy between our negative results and 
the positive effects of pretreatment of the injection site on migration in mice skin. 
First, closer analysis of the results in mouse models by Martin-Fontecha et al. 
revealed that migration rates were indeed dramatically increased by conditioning but 
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even in their experiments never exceeded approximately 2% (3). Conditioning of the 
skin was only effective in increasing the migration of suboptimal doses of DC from 
0.01-0.1% to 1%. No increases in migration rates were observed when the migration 
rate of the untreated control was around 1-2%. Moreover, high doses of TNFα have 
been demonstrated, to the contrary, to inhibit migration from the skin (22). Thirdly, 
the timing of pretreatment is critical. Clinical studies show that intradermal 
administration of TNFα or IL1-β induced the emigration of resident Langerhans cells 
to draining LN. In this setting, application of those pro-inflammatory cytokines may 
act both directly on the DC and indirectly via the surrounding accessory cells. In our 
study, TNFα is injected to the skin 8 hours prior to DC vaccination and will therefore 
exert its effect on the microenvironment and not directly on the DC. Given the burden 
for patients in terms of injections and logistics, we chose not to titrate the dose and 
timing of TNFα to find the optimum. Moreover, Nair et al demonstrated that by 
conditioning the skin with the TLR-ligand imiquimod, the migration of immature DC 
could be stimulated (21). However, even in this trial no improvement in migration rate 
was achieved as the injected DC had a mature, and thus highly migratory, 
phenotype. Finally, note that while several factors contribute to the migration of DC, 
these can be very difficult to study individually and even more so when considering 
the costs and logistics of a clinical study. Hence, such factors may best be studied in 
vitro before final optimization in vivo.  
The use of 19F MRI for quantitative cell tracking is a relatively new technique (12). 
Here we applied this technology to track migratory DC over 10 hours, in order to 
optimize the cell numbers used in DC vaccinations in the clinic. This technique 
allows us to use a wide range of cell numbers, up to the millions of cells that are 
typical for current DC vaccination and to use opaque samples, such as tissue. Other 
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migration assays require either small cell numbers or transparent samples (23). The 
19F particles used to label the DC are not toxic to the cells and do not affect their 
migration, when compared to unlabeled cells (24). The expression of typical cell 
surface markers, used in chemotaxis and migration, is also unaffected. Although 19F 
MRI has not currently been applied to clinical cell tracking, the technique will be 
available for the clinic in the near future. The label we used here can also be 
adapted for clinical use. Furthermore, the assay conditions can easily be modified to 
include different cytokines or combinations of cytokines to study their effect on 
migration. Different cell types can also be used, as long as the cells can be labeled 
with a 19F agent. Some 19F labels may also be sensitive to oxygen partial pressures, 
and thus these can be measured during the experiments to indicate hypoxic regions. 
In this paper, we used bovine tissue instead of human tissue to avoid differences 
due to mismatched immune cells and the inflammatory condition of the tissue. 
However, the assay can readily be adapted to use other tissue types. Here we used 
CCL21 to provide a chemotactic gradient for DC migration. CCL21 is known to 
induce the active migration of DCs towards lymphatic vessels in vivo (25). 
One of the main issues with 19F MRI is its sensitivity in terms of detectable 
cells/voxel/unit imaging time. Under our conditions, we found the sensitivity to be 
higher than that of clinical scintigraphy (Figure 5A); the sensitivity in our set-up 
allows the detection of as little as 5000 cells/voxel, compared to 2×104 with 
scintigraphy (16). This is 4-fold higher than the sensitivity of scintigraphy in vivo. 
Note that the MRI was carried out on a clinical scanner using sequences that can be 
applied to humans; using a higher field research magnet and faster imaging 
sequences would improve sensitivity further. In our experiments, we chose to 
measure only migration in the vertical plane (i.e. along the chemokine gradient), as 
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we felt this was the most relevant direction. However, it would certainly be feasible to 
measure migration in both planes or even in 3D in this setup. Furthermore, the 
relatively poor sensitivity of scintigraphy might be one reason why smaller numbers 
of migratory cells are not detected, and thus the percentage of migratory cells 
calculated is artificially low, especially when smaller cell numbers were injected 
initially. Although the spatial resolution has improved with more recent nuclear 
imaging modalities (SPECT, SPECT/CT) it is still far behind on MRI especially in soft 
tissues like LN. We previously demonstrated examination of intra-LN distribution of 
labeled DC using MRI with iron-loaded cells (16).  
The high density of cells at the injection site may prevent the access to sufficient 
oxygen and nutrients, and may therefore hamper cell movement and active 
migration. Indeed, hypoxia is evident at the injection site (Figure 4C). Hypoxia 
suppresses the production of matrix metallo-proteinases and the migration of human 
monocyte derived-DC (3). After injection of a cell suspension in the dermis, the fluid 
will be readily drained into the afferent lymphatic vessels, due to elasticity of the skin. 
The cells however, will be caught in the extracellular matrix and will be packed 
together, devoid of nutrients and oxygen. The cells on the border of the injection 
depot may have the opportunity to move away from the depot.  
The optimal numbers of DC per LN for adequate immune induction in clinical studies 
has not been established. Some studies report a dose-dependent relation with 
immune responses in human (26, 27). Given the high immune stimulating potential 
of DC in vitro, it may not be surprising that even small numbers of DC, as in clinical 
studies, are sufficient. Indeed, we have shown previously that even small numbers of 
DC are capable of effective interacting with T cells (10, 15). Hypothetically, the 
unfavorable conditions at the site of delivery may select the most fit DC with high 
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stimulatory potency, or simply those at the periphery of the bolus, which are then 
able to migrate to the LN and adequately induce immune responses. Combining this 
information with the current data, we suggest that multiple intradermal injections with 
small numbers of cells to target multiple LN basins would increase DC migration to 
LN, for example using a ‘tattoo’ delivery device (28). In particular, cells that appear to 
be actively migratory were only evident with the lower cell numbers (Figure 4C). It is 
possible that DC aggregation or chemotaxis could also be involved in reducing 
emigration with larger cell numbers, although these factors were not studied here.  
In conclusion, we have shown that pretreatment of the skin to create an inflammatory 
microenvironment at the injection site does not improve DC migration to LN after i.d. 
delivery. To the contrary, we demonstrate that reduction of cell density at the 
injection site is key to improved DC migration, both in vitro and in vivo. Since current 
imaging modalities for clinical in vivo tracking of DC are not sensitive enough to 
study migration of small numbers of DC, the in vitro model developed here facilitates 
further studies for improving migration rates.  
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Figure legends 
 
Figure 1. Pretreatment of the skin does not improve DC migration. 
Migration of DC to skin-draining LN (n=18) was monitored after intradermal injection 
with 15×106 111In-labeled DC vaccine and planar scintigraphy of injected region. (A) 
The percentage of migrating DC at 24 or 48 hrs post-injection, or after different 
pretreatments, never exceeded 4% of the total cells injected. Statistical analyses 
using a two-tailed unpaired t-test showed no significant differences between the 
experimental conditions or migration at 48 hours after intradermal migration without 
pretreatment. (B) For each pretreatment condition, TNFα (n=3), GM-CSF (n=3), 
Imiquimod (n=4) or unloaded but activated DC 6 hours (n=3) or 24 hours (n=3) prior 
to vaccination, the individual images are shown. Upon GM-CSF addition, the 
induration and migration at the site of injection was markedly larger than after 
injection of DC alone, suggesting random migration into surrounding dermis. The 
arrows indicate the pretreated site.  
 
Figure 2. Immunohistochemical analyses of the injection site.  
We performed histological analysis of the pretreatment injection sites 48 hours post-
injection in order to validate our imaging findings. (A-C) Pretreatment of the injection 
site with TNFα, GM-CSF or unloaded DC, consistently induced local inflammation, 
demonstrated by infiltrates of leukocytes around vessels in the dermis, mainly 
neutrophils and eosinophils. Within areas with high cell density, especially at the 
injection sites, there is a high proportion of dying cells, including vaccine-DC. (D) 
Normal skin from patient in Figure 2C, for comparison.  
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Figure 3. In vitro model to study migration of small numbers of cells.  
(A) Cell bolus position within the sample. Overlay of a 1H MRI image and 19F CSI 
cell map showing the position and the density of the cell bolus injection in the tissue 
sample.  The migration region is vertically above the cell pellet and the control region 
below. (B) The panels show representative data obtained at 1, 5 and 9 hrs after 
injection of 5×106 DCs, plotted in mm. The scale bar represents the number of cells. 
 
Figure 4. Reducing the cell density improves migration rates in vitro. 
The change in time in the cell numbers within the migration and the control regions 
are plotted for 5×106 DCs (n=3). (A) A clear trend is observed for the cell number 
with time dependence in the migration region (left, in red); improved migration is 
observed for 5×106 and 1×106 cells (not shown). No pattern is observed for the 
control region (right, in blue). (B) Summary of three individual experiments with 
varying cell numbers in the in vitro assay. The data indicate that increasing cell 
number suppresses migration. Thus, the percent of migratory cells is nearly 3% with 
0.5 ×106 and 0% with 15×106 DCs. Average and standard deviation are indicated. 
(C) Sections from the tissue used for the migration assay were cut and stained for a 
hypoxia marker (dark stain); cell nuclei are stained lighter. Nuclei are sparse in the 
surrounding muscle tissue. Representative images are shown for 10×106 DC (top; 
low magnification), and 1×106 DC (low and high magnification respectively). 
Migratory cells are evident in the lower panels. 
 
Figure 5. Reducing the cell density improves migration rates in vivo. 
Migration of DC to skin-draining LN was monitored after intradermal injection with 
reduced numbers of 111In-labeled DC vaccine and planar scintigraphy of injected 
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region. (A) The percentage of migration with 15×106 DC at 48 hrs post-injection (as a 
reference), 5×106 (n=4), 5×105 DC (n=4) or TNFα pretreatment together with 5×106 
cells (n=2). The mean percentage of migration with 5×106 DC was 2.6%, significantly 
higher than 15×106 DC (p=0.0496, unpaired two-tailed t-test), whereas further 
reduction of cell number or pretreatment with TNFα combined with reduced cell 
number, did not significantly improve migration rates (“n.s.” denotes not significant). 
(B) For each condition with reduced number of cells, the individual images are 
shown. The arrows indicate the experimental site.  
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